At its Sept. 14, 2026 interim results briefing, Junshi Biosciences said JS203 (CD20/CD3 bispecific) is expected to initiate Phase III trials in 2026. JS207 (PD-1/VEGF bispecific) is in Phase II and is being tested in combination with chemotherapy, monoclonal antibodies and ADCs across multiple tumor types; Junshi plans to start Phase III for JS207 in 2026.

China's National Bureau of Statistics said its monitoring of 50 key production-input prices across nine categories showed 37 rises, nine falls and four unchanged in early September 2026 versus late August. Three-way crossbred live hogs were priced at 11.00 yuan/kg, up 0.9% sequentially.

On the 13th (local time), Israeli Defense Minister Katz said the IDF will continue to hold the Aritashir high ground in southern Lebanon to prevent Hezbollah or any other force from returning and re-establishing positions. Katz said the position is part of what Israel describes as its 'security zone' in southern Lebanon and that Israeli forces will not withdraw or redeploy until Hezbollah is disarmed across Lebanon. He warned anyone approaching the position would be eliminated.